Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program

Completed

• Conditions: Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting
• Interventions: Drug: Interferon Beta Therapy

• Registration Number: NCT04655222
• Lead Sponsor: Biogen

Brief Summary

The primary objective(s) of the study is to evaluate the impact of exposure to SC Peginterferon beta-1a or IM Interferon beta-1a before and during pregnancy on pregnancy outcome in female participants who had registered in the German Patient Support Program (PSP) and of whom a pregnancy report and pregnancy outcome report is available.

The secondary objectives of this study are applicable for a subpopulation of the above-mentioned population, i.e. for participants of whom data on a standardized questionnaire collected during a telephone interview is available.

Detailed Description

This is an observational study with focus on existing pregnancy reporting forms (retrospective part) and a patient's questionnaire which is completed at a single point of time (prospective part). Main data source for the retrospective data (from 2014 until December 2019) will be captured from multiple sclerosis service-center (MSSC) database, i.e. the entered pregnancy report (to be completed as soon as pregnancy becomes known) and pregnancy outcomes report (to be completed after completion of pregnancy).

Prospective data (December 2020 to 31 March 2021) will be captured as standardized ePDF questionnaire completed during telephone interview. If the pregnancy report or the pregnancy outcome report is incomplete, i.e. the data above was not collected, the open questions will be addressed during a telephone interview performed by the MSSC and the new information will be entered into the MSCC database. The patient questionnaire will be completed at a single point of time during the telephone interview performed by the MSSC.

Study Timeline

• Study First Submitted: 2020-11-30
• Study First Submitted QC: 2020-11-30
• Study First Posted: 2020-12-07
• Study Start: 2021-04-30
• Primary Completion: 2021-10-15
• Study Completion: 2021-10-15
• Status Verified: 2023-04
• Last Update Submitted: 2023-04-13
• Last Update Posted: 2023-04-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 470

Inclusion Criteria

• Diagnosed relapsing-remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS) (CIS indication only applicable for interferon beta-1a)
• Exposure to either SC Peginterferon beta-1a therapy or an IM Interferon beta-1a therapy before or during pregnancy
• Registered in the PSP of the multiple sclerosis service- center (MSSC) and agreed in writing to the privacy policy of the registration form
• Reported pregnancy data (pregnancy report and pregnancy outcome report) available at MSSC. Note: only pregnancy data (i.e. obtained until 15 October 2020) will be considered.
• Pregnancy outcome in the retrospectively collected data was a live birth

Read More

Exclusion Criteria

Any criteria that does not fulfil the above-mentioned inclusion criteria.

NOTE: Other protocol defined Inclusion criteria may apply

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
All Participants	Interferon Beta Therapy	Pregnant Multiple Sclerosis (MS) participants treated with SC interferon beta therapy or an IM interferon beta therapy in the German PSP of the MSSC.

Primary Outcome Measures

Name	Time	Method
Percentage of Participants With Ectopic Pregnancies	8 weeks of gestation
Percentage of Participants With Stillbirths	from 22 week up to 39 weeks of gestation	A still birth is defined as fetal death at \>22 weeks gestation.
Percentage of Participants With Live Births Without Congenital Anomalies	up to end of study (4 months)
Percentage of Participants With Elective Abortions	up to Week 20 of gestation
Percentage of Participants With Live Births With Congenital Anomalies	up to end of study (4 months)
Percentage of Participants With Spontaneous Abortions	up to 22 weeks of gestation	A spontaneous abortion is defined as fetal death before 22 weeks of gestation.
Percentage of Participants With Preterm Births	up to 37 weeks of gestation	A preterm birth is a birth before 37 completed weeks of gestation.

Secondary Outcome Measures

Name	Time	Method
Average Head Circumference of the Children	From Birth up to Month 48
Percentage of Abnormalities Diagnosed During Pediatric Check-ups	up to Month 48
Time to First Multiple Sclerosis (MS) Relapse After Introduction of the First Supplemental Feedings in Women With Subcutaneous Peginterferon Beta-1a or Intramuscular Interferon Beta-1a Therapy During Lactation	up to end of study (4 months)
Percentage of Women Restarting Subcutaneous Peginterferon Beta-1a or Intramuscular Interferon Beta-1a Therapy After Birth	up to end of study (4 months)
Duration of Subcutaneous Peginterferon Beta-1a or Intramuscular Interferon Beta-1a Therapy Exposed Breastfeeding	up to end of study (4 months)
Average Length of the Children	From Birth up to Month 48
Percentage of Women Discontinued Subcutaneous Peginterferon Beta-1a or Intramuscular Interferon Beta-1a Therapy During Pregnancy	up to 39 weeks of gestation
Percentage of Women Starting Subcutaneous Peginterferon Beta-1a or Intramuscular Interferon Beta-1a Therapy During Pregnancy	up to 39 weeks of gestation
Time to Restart Subcutaneous Peginterferon Beta-1a or Intramuscular Interferon Beta-1a Therapy in Relation to Birth	up to end of study (4 months)
Time to Start Another MS Therapy During/After Pregnancy in Relation to Birth	up to end of study (4 months)
Change From Baseline Expanded Disability Status Scale (EDSS) During and After Pregnancy to Expanded Disability Status Scale (EDSS) Before Pregnancy	Week 0 up to Week 39 of gestation	EDSS is based on a standardized neurological exam and focuses on symptoms that commonly occur in multiple sclerosis (MS). Scores range from 0.0 (normal) to 10.0 (death due to MS).
Number of Women Breastfeeding Under Subcutaneous Peginterferon Beta-1a or Intramuscular Interferon Beta-1a Therapy	up to end of study (4 months)
Average Weight of the Children	From Birth up to Month 48
Time to Discontinuation of Subcutaneous Peginterferon Beta-1a or Intramuscular Interferon Beta-1a Therapy in Relation to Beginning of Pregnancy	up to 39 weeks of gestation
Time to Start Subcutaneous Peginterferon Beta-1a or Intramuscular Interferon Beta-1a Therapy in Relation to Beginning of Pregnancy	up to 39 weeks of gestation
Percentage of Women Starting Another Multiple Sclerosis (MS) Therapy During/After Pregnancy	up to end of study (4 months)
Percentage of Women Using Other Therapies During Pregnancy	up to 39 weeks of gestation
Percentage of Multiple Sclerosis Relapses in Women with Subcutaneous Peginterferon Beta-1a or Intramuscular Interferon Beta-1a Therapy Before, During and After Pregnancy	up to end of study (4 months)

Trial Locations

Locations (1)

Research Site; 🇩🇪 Göttingen, Germany